We are live on ! Find out more
B

Bailard Portfolio holdings

AUM $4.35B
1-Year Est. Return 23.57%
This Fund
S&P 500
This Quarter Est. Return
-12.09%
1 Year Est. Return
+23.57%
3 Year Est. Return
+74.84%
5 Year Est. Return
+96.64%
10 Year Est. Return
+374.16%
AUM
$2.54B
AUM Growth
-$433M
Cap. Flow
-$21.4M
Cap. Flow %
-0.84%
Top 10 Hldgs %
31.88%
Holding
847
New
132
Increased
213
Reduced
233
Closed
169

Sector Composition

Rank Sector Weight
1 Technology 17.33%
2 Healthcare 8.9%
3 Financials 6.63%
4 Consumer Staples 4.45%
5 Communication Services 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LIAN
651
DELISTED
LianBio American Depositary Shares
LIAN
$103K ﹤0.01%
47,597
+10,697
+29% +$36.3K
HBIO icon
652
Harvard Bioscience
HBIO
$28.1M
$97K ﹤0.01%
+2,685
New +$121K
ETNB
653
DELISTED
89bio
ETNB
$96K ﹤0.01%
+29,692
New +$89.6K
ASRT
654
DELISTED
Assertio
ASRT
$94K ﹤0.01%
+2,113
New +$88K
NGNE icon
655
Neurogene
NGNE
$709M
$93K ﹤0.01%
+4,505
New +$110K
ONCT
656
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$93K ﹤0.01%
+4,210
New +$93.9K
SEAT icon
657
Vivid Seats
SEAT
$72.6M
$92K ﹤0.01%
+615
New +$111K
TYRA icon
658
Tyra Biosciences
TYRA
$1.83B
$92K ﹤0.01%
+12,910
New +$103K
NHS
659
Neuberger High Yield Strategies Fund Inc
NHS
$252M
$91K ﹤0.01%
10,839
OLMA icon
660
Olema Pharmaceuticals
OLMA
$1.03B
$91K ﹤0.01%
+22,400
New +$71K
CASI
661
DELISTED
CASI Pharmaceuticals
CASI
$90K ﹤0.01%
31,530
+29,020
+1,156% +$126K
AQB icon
662
AquaBounty Technologies
AQB
$4.81M
$87K ﹤0.01%
+2,551
New +$77.9K
HOWL icon
663
Werewolf Therapeutics
HOWL
$17.9M
$87K ﹤0.01%
+21,200
New +$96.7K
ORKA
664
Oruka Therapeutics
ORKA
$5.54B
$87K ﹤0.01%
+2,917
New +$82.5K
KLRS
665
Kalaris Therapeutics
KLRS
$92.8M
$85K ﹤0.01%
+952
New +$99.8K
VISN
666
Vistance Networks Inc
VISN
$2.69B
$78K ﹤0.01%
12,800
-41,000
-76% -$286K
ELA icon
667
Envela
ELA
$544M
$71K ﹤0.01%
+10,000
New +$54.3K
ELDN icon
668
Eledon Pharmaceuticals
ELDN
$288M
$67K ﹤0.01%
27,413
-187
-0.7% -$571
RNAC icon
669
Cartesian Therapeutics
RNAC
$233M
$66K ﹤0.01%
+1,667
New +$49.4K
LYTS icon
670
LSI Industries
LYTS
$858M
$62K ﹤0.01%
10,000
-32,267
-76% -$207K
LPCN icon
671
Lipocine
LPCN
$18.1M
$60K ﹤0.01%
+4,376
New +$68.2K
TERN
672
DELISTED
Terns Pharmaceuticals
TERN
$50K ﹤0.01%
+20,300
New +$40.5K
QTTB icon
673
Q32 Bio
QTTB
$458M
$47K ﹤0.01%
+1,319
New +$45K
MNOV icon
674
MediciNova
MNOV
$64.5M
$44K ﹤0.01%
17,507
-10,715
-38% -$28K
CYT
675
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$42K ﹤0.01%
+13,900
New +$35.5K

Similar funds

Bailard's Q2 2022 Portfolio in Review

As of Q2 2022, Bailard held 847 positions worth $2.54B, down 15% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bailard's Q2 2022 filing shows 132 new, 213 increased, 233 reduced and 169 closed positions. Its largest new stake was iShares 1-3 Year Treasury Bond ETF: 813,570 shares worth $67.4M. The largest sale was SPDR Gold Trust, an estimated $76.3M.

By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 19% a quarter earlier, followed by Healthcare and Financials.

  • Bailard's largest Q2 2022 buy was iShares 1-3 Year Treasury Bond ETF: 813,570 shares worth $67.4M.
  • Bailard added most to State Street SPDR Bloomberg 1-3 Month T-Bill ETF in Q2 2022, an estimated $140M increase.
  • Bailard's biggest Q2 2022 reduction was SPDR Gold Trust, cutting an estimated $76.3M.
  • Bailard fully exited ZYNGA INC. CL A COMMON in Q2 2022, selling an estimated $3.67M.
  • Bailard's ten largest holdings make up 32% of its $2.54B portfolio in Q2 2022.
  • Bailard opened 132 new positions and closed 169 in Q2 2022.
  • Bailard's portfolio value fell 15% quarter-over-quarter to $2.54B.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.